Mozessohn L, Buckstein R. Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?. haematol [Internet]. 2020Sep.10 [cited 2025Dec.5];. Available from: https://haematologica.org/article/view/12147